Myomo
Myomo develops and markets the MyoPro, a powered upper-limb orthosis using non-invasive EMG sensors to restore arm and hand function for patients with stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions.
- Company typePublic
- Founded2006
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Myomo does
Myomo is a publicly traded medical robotics company (NYSE American: MYO) that develops and commercializes the MyoPro product line, a family of FDA Class-2 powered upper-limb orthoses designed to restore arm and hand function in patients with stroke, brachial plexus injury, cerebral palsy, ALS, multiple sclerosis, and other neuromuscular conditions. The core technology uses non-invasive surface electromyography (EMG) sensors to detect the patient's own residual muscle signals, which are then amplified to drive small motors providing elbow flexion/extension, wrist movement, and hand grasping (including 3-jaw chuck grasp). The technology was originally developed at MIT and Harvard Medical School, with Myomo holding exclusive license to foundational MIT patents since spinning out in 2006. Current products include the MyoPro 2x (latest generation launched April 2025), MyoPro Motion-G, MyoPro Motion-W, and MyoPro 2+, supported by the Myomo Mobile App for remote EMG customization and the MyoConfig clinical software platform. Regulatory clearances span FDA, CE Mark, and Health Canada, with dedicated Medicare DMEPOS fee schedule codes L8701 and L8702.
The company generates revenue primarily through hardware sales of MyoPro devices at an average selling price of $58,800, with reimbursement sourced from Medicare Part B, commercial payers via an Elevance Health network participation agreement covering 80+ million lives, and international government health programs including German statutory health insurance. Distribution is hybrid: certified prosthetist and orthotist practices (300+ trained Certified Prosthetists Orthotists as of Q1 2025), an exclusive global partnership with Ottobock (the world market leader in technical orthopedics), Ottobock Care clinics nationwide, and regional international distributors across Australia/New Zealand, Italy, and the UK. The company also sells direct-to-consumer through its website, screening events in 20+ cities, and the MyoConnect clinician referral program. Recurring patient sources grew from 25% of revenue a year ago to 49% in Q1 2026, indicating a maturing revenue base weighted toward existing patient upgrades and replacements rather than first-time acquisition.
Myomo is headquartered in Burlington, Massachusetts, employs 101-250 people, and went public in June 2017 via a historic SEC Regulation A+ IPO on NYSE MKT. The company has subsequently raised additional capital through multiple public equity offerings (totaling approximately $36.4 million in 2017-2024) and a $17.5 million debt facility from Avenue Capital in November 2025, while remaining unprofitable with FY2025 EBITDA of approximately -$13.5 million on $40.9 million in revenue. Gross margins stand at 68.2% (Q1 2026), reflecting the hardware-intensive medical device cost structure.
Myomo firmographics
Firmographics- Name
- Myomo
- Legal name
- Myomo, Inc.
- Website
- https://myomo.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Myomo develops and markets the MyoPro, a powered upper-limb orthosis using non-invasive EMG sensors to restore arm and hand function for patients with stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions.
- Ownership category
- akta.pro rank
Myomo industry classification
Industry- Product category
- Powered Orthotic Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Orthotics & Bracing (AFO/KAFO, Spinal, Soft Goods Supports) (HLAHAMAC)
- akta.pro secondary industries
- Orthotics & Bracing (Spinal/Lower/Upper Extremity Orthoses) (HLAHAEAI), Hand & Upper Extremity Therapy (OT/CHT) (HSADAIAH)
Keywords
Where Myomo is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Myomo business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- MyoPro Device Sales: Myomo generates revenue primarily through the sale of MyoPro powered arm orthoses to patients. The average selling price is approximately $58,800. Revenue recognition depends on insurance authorization and reimbursement, with growing recurring patient sources representing 49% of Q1 2026 revenue versus 25% a year ago.
- Insurance Reimbursement: Myomo derives significant revenue from insurance payer reimbursements including Medicare Part B, commercial insurance through network agreements (Elevance Health with 80+ million covered lives), and international government health programs (German statutory health insurance).
- Digital Health Services: With the launch of Myomo Mobile App, the company is building a connected digital ecosystem around its MyoPro device, capturing usage data for reimbursement support and product development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | MyoPro powered arm orthosis with average selling price of $58,800 |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels7 records
Myomo product offering
Product offeringCore offering
Myomo designs, manufactures, and sells the MyoPro family of powered upper-limb orthoses that use non-invasive surface EMG sensors to detect and amplify a patient's own muscle signals, driving small motors to assist with elbow flexion/extension, wrist movement, and hand grasping. The devices are prescribed for individuals with arm paralysis or weakness from stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions, fitted by certified prosthetists/orthotists, and reimbursed primarily through Medicare Part B, commercial insurance (e.g., Elevance Health), and international health systems.
Product overview
Myomo is a medical robotics company that develops and markets the MyoPro product line—a family of powered upper-limb orthoses designed to restore function to paralyzed or weakened arms for patients with neurological disorders including stroke, brachial plexus injury, traumatic brain/spinal cord injury, ALS, cerebral palsy, and other neuromuscular conditions. The core MyoPro products (MyoPro 2x, Motion-G, Motion-W) are wearable braces that detect the patient's own EMG signals through non-invasive sensors, amplifying them to drive motors that assist with arm and hand movement. The product portfolio includes current generations (MyoPro 2x, MyoPro 2+) and legacy versions, supported by the Myomo Mobile App for remote device management and MyoConnect/MyoCare service programs. The MyoPro is currently the only marketed device in the U.S. that uses EMG sensing to restore activities of daily living.
Differentiator
Problem solved
Functional benefit
Brands
- MyoPro: The company's primary product line - powered upper-limb orthosis designed to help regain function in arms and hands paralyzed by stroke, brachial plexus injury, cerebral palsy, or other neuromuscular conditions
- MyoPro Motion-G
- MyoPro Motion-W
- MyoPro 2x
- MyoConnect
- MyoCare
- Myomo Mobile App
- MyoPro For Veterans
Products and services
- MyoPro 2x Latest generation powered arm orthosis using EMG sensors to detect muscle signals and drive motors, restoring function for activities of daily living in users whose arms are paralyzed or weakened by stroke, brachial plexus injury, cerebral palsy, or other neuromuscular conditions.
- MyoPro 2+ Powered upper-limb orthosis version with enhanced features designed for patients with neurological disorders and upper-limb paralysis.
- MyoPro Motion-G Powered orthosis providing elbow flexion/extension and powered grasping (3-jaw chuck grasp capability) for individuals with upper extremity paresis; detects EMG signals in bicep/tricep and forearm to enable voluntary control of partially paralyzed arms.
- MyoPro Motion-W Elbow-wrist-hand orthosis variant with articulating handpiece providing wrist and hand support for patients with upper limb weakness or partial paralysis.
- Myomo Mobile App Mobile application for clinicians and patients using the MyoPro, enabling remote customization of EMG settings, real-time visualization of muscle activity, and capture of usage data to support reimbursement claims and product development.
Quantifiable outcome
- 47% average improvement in Fugl-Meyer Scale scores for chronic stroke patients using MyoPro
- +4 more outcomes
Companies that use Myomo
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles4 records
Myomo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Myomo partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Elevance HealthcoreMyomo entered into network participation agreements with Elevance Health covering Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans effective through 2026. The agreements add 45 million medical members, expanding coverage to over 80 million covered lives for MyoPro orthoses.
- HOMELINKminorMyomo signed agreement with HOMELINK enabling the company to bill in-network with 1,200 payers for processing out-of-network claims for MyoPro powered orthosis.
- Hobbs RehabilitationminorMyomo partnered with Hobbs Rehabilitation to provide services supporting MyoPro users in the UK. Hobbs neurological physiotherapists and occupational therapists work with patients using MyoPro family of myoelectric orthotics.
- NeuroMuscular Orthotics Pty Ltd (NMO)minorMyomo signed agreement with NMO to offer MyoPro across Australia and New Zealand markets.
- Progettiamo Autonomia Robotics (PAR)minorMyomo signed agreement with PAR, a unit of Progettiamo Autonomia headquartered in Reggio Emilia, Italy with 17 offices nationwide, to offer MyoPro in Italy.
- OttobockcoreOttobock, a world market leader in technical orthopedics, entered into an exclusive global distribution agreement for MyoPro starting January 1, 2017. The partnership enables Ottobock to address unmet needs of individuals with upper extremity paralysis through Myomo's myoelectric orthotic technology. Myomo expanded availability through Ottobock Care clinics in 2026.
Scale indicators10 records
Recent moves10 records
Expansion highlights6 records
Myomo competitors and assessment
Company assessmentDirect peers
- Ekso Bionics: Developer of wearable robotic exoskeletons for rehabilitation and mobility. Comparable as a publicly traded rehabilitation robotics company targeting stroke and spinal cord injury, addressing overlapping patient populations with a different (lower-limb) product focus.
- Hanger, Inc. Largest U.S. provider of orthotic and prosthetic clinical services. Hanger's network of O&P patient-care centers is the same clinical channel through which MyoPro is fitted and reimbursed, making it the most relevant service-side peer.
- Össur: Global leader in orthotics and prosthetics, including upper-limb solutions. Directly comparable product portfolio (bracing and prosthetic components) and overlapping clinical channels make it Myomo's closest public peer in non-invasive orthotic technology.
- Saebo: Specialist in upper-extremity rehabilitation devices for stroke survivors (e.g., SaeboGlove, SaeboReach). Directly comparable in target patient (stroke-related hand/arm impairment), clinical channel (OT/PT), and reimbursement-driven commercial model.
- ReWalk Robotics: Pioneer in wearable robotic exoskeletons for spinal cord injury and stroke rehabilitation. Comparable as a small-cap public peer in powered rehabilitation wearables, with similar payer-reimbursement dynamics and clinical-evidence requirements.
- Fillauer: Manufacturer of prosthetic and orthotic components with global O&P distribution. Comparable in product scope (upper-limb orthotics/prosthetic components) and clinical channel, though without Myomo's powered/myoelectric specialization.
Emerging players
- Bionik Laboratories: Robotic rehabilitation technology company focused on upper and lower extremity therapy. Comparable as a smaller, R&D-stage peer pursuing similar neuro-rehabilitation applications with overlapping target patient populations.
- Synapse Biomedical: Developer of EMG-driven neurostimulation devices (e.g., for diaphragm pacing). Comparable as a niche EMG-based neurotechnology company working in the broader neuromuscular rehabilitation space with similar clinical and regulatory pathways.
Broad incumbents
- Ottobock: World market leader in technical orthopedics and Myomo's exclusive global distribution partner. Comparable in upper-limb orthotics and prosthetics, with a much broader portfolio across mobility, prosthetics, and patient care; operates as both partner and adjacent competitor.
- Parker Hannifin: Industrial motion and control conglomerate that also sells the Indego powered orthosis through its Human Motion & Control business. Comparable as a broad incumbent entering the powered lower-extremity orthosis/exoskeleton category with similar payer and clinical dynamics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Myomo social profiles
Digital presenceMyomo compliance and trust
Trust signalCompliance8 records
Myomo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Myomo leadership team
Management profileNumber of profiles
Profiles5 records
Myomo subsidiaries and ownership
Company hierarchySubsidiaries1 record
Myomo funding detail
Funding detailFunding overview
Funding rounds10 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Myomo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Myomo
What does Myomo do?
Myomo designs, manufactures, and sells the MyoPro family of powered upper-limb orthoses that use non-invasive surface EMG sensors to detect and amplify a patient's own muscle signals, driving small motors to assist with elbow flexion/extension, wrist movement, and hand grasping. The devices are prescribed for individuals with arm paralysis or weakness from stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions, fitted by certified prosthetists/orthotists, and reimbursed primarily through Medicare Part B, commercial insurance (e.g., Elevance Health), and international health systems.
Is Myomo a public or private company?
Myomo is a public company. It is classified as public and is currently operating.
When was Myomo founded?
Myomo was founded in 2006. It employs 101 to 250 people.
Where is Myomo based?
Myomo is headquartered in Cambridge, United States, in the North America region.
How does Myomo make money?
Three revenue lines are on record. MyoPro Device Sales are the primary driver. The others are insurance Reimbursement and digital Health Services.
Who are Myomo's main competitors?
Direct peers on record are Ekso Bionics, Hanger, Inc., Össur, Saebo, ReWalk Robotics and Fillauer. Emerging players are Bionik Laboratories and Synapse Biomedical. Broad incumbents are Ottobock and Parker Hannifin.
Does Myomo have an API?
No public API is recorded for Myomo.
What industry is Myomo in?
Myomo's product category is Powered Orthotic Medical Devices. Its primary akta.pro industry code is HLAHAMAC, Orthotics & Bracing (AFO/KAFO, Spinal, Soft Goods Supports), with a secondary code of HLAHAEAI, Orthotics & Bracing (Spinal/Lower/Upper Extremity Orthoses). Its NAICS code is 339113 and its SIC code is 3842.